Navigation Links
AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Date:5/9/2013

tiation of human clinical trials, potentially addressing one of the major health risks facing both Russia and the rest of the world," remarked Andrey Boldyrev , General Director of CardioNova. "We are currently working with the CRO and the trial centers to distribute the approved protocol and making final preparations for the initiation of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
(Date:6/2/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in ... that Dr. Pamela Pavco , RXi,s ... 23 rd World Congress of Dermatology ... in-depth presentations by world-class clinicians and/or investigators, ...
(Date:6/2/2015)... , June 2, 2015 GOJO, inventors ... its commitment to antibiotic stewardship at the White House ... and animal health organizations and stakeholders at the White ... years to slow the emergence of antibiotic-resistant bacteria, detect ... and prevent the spread of resistant infections. ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. ... the Moenninghoff product line . , ... announce that the R.M. Hoffman Company will be representing ... in 1916, this is a strategically important step. ... of professional distributor we need to successfully grow our ...
Breaking Biology Technology:BioClinica Names David Peters New Chief Financial Officer 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3
... Feb. 16, 2011 / PRNewswire/ -- Sigma-Aldrich® ... following executive leadership appointments intended to more closely ... Frank Wicks, President Research, will assume ... including those in Research Essentials, Research Specialties and ...
... PARK, N.C., Feb. 16, 2011 Chimerix, Inc., a ... that it has been awarded a contract by the ... advanced development of Chimerix,s broad spectrum antiviral drug candidate, ... a smallpox release. CMX001 is a ...
... Stryker Corporation,s Orthopaedics division today announced at ... conference the findings of the National Joint Registry ... Trident® Cup, Accolade® Hip Stem and Triathlon® Knee ... revision rates for the most frequently used brands.(1,2,3) ...
Cached Biology Technology:Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 2Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 3Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales 4
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... America will hold its 93rd annual meeting on Aug. ... founded in 1915 to promote the practice and awareness ... the interdisciplinary nature of ecology and linking research with ... will be presented at the meeting, including a number ...
... professor and Georgia Research Alliance Eminent Scholar of Molecular ... $9.2 million as part of a major new research ... part of the National Institutes of Health. Dalton,s ... biology, will address the molecular underpinnings of the early ...
... CLEVELAND As Ohio and Michigan fruit and vegetable ... data about the eating choices of Latino migrant children ... gathered this summer will help migrant families understand why ... epidemic and contribute to new interventions to combat this ...
Cached Biology News:ESA to feature wide range of UW-Madison presentations 2ESA to feature wide range of UW-Madison presentations 3ESA to feature wide range of UW-Madison presentations 4ESA to feature wide range of UW-Madison presentations 5ESA to feature wide range of UW-Madison presentations 6ESA to feature wide range of UW-Madison presentations 7ESA to feature wide range of UW-Madison presentations 8UGA researchers win $9.2 million stem cell grant from NIH 2Case Western Reserve University study looks at keeping migrant workers' children healthy 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: